Literatura científica selecionada sobre o tema "Response to therapies"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Índice
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Response to therapies".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Response to therapies"
Gayan, Chathura. "Evaluate the response of Apoptosis, Angiogenesis and Cancer Therapies". Cancer Research and Cellular Therapeutics 2, n.º 1 (28 de março de 2018): 01–08. http://dx.doi.org/10.31579/2640-1053/022.
Texto completo da fonteDudekula, Noor, Vikas Arora, Zsuzsanna Callaerts-Vegh e Richard A. Bond. "The Temporal Hormesis of Drug Therapies". Dose-Response 3, n.º 3 (1 de maio de 2005): dose—response.0. http://dx.doi.org/10.2203/dose-response.003.03.009.
Texto completo da fonteTruelove, Edmond, Kimberly Hanson Huggins, Lloyd Mancl e Samuel F. Dworkin. "NONSPLINT THERAPIES: Authors' response". Journal of the American Dental Association 137, n.º 11 (novembro de 2006): 1493–94. http://dx.doi.org/10.14219/jada.archive.2006.0070.
Texto completo da fontePrasad, Vinay, Victoria Kaestner e Alyson Haslam. "Bridging therapies used in trials testing CAR-T therapies." Journal of Clinical Oncology 42, n.º 16_suppl (1 de junho de 2024): e19011-e19011. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e19011.
Texto completo da fonteBrown, Barbara G. "Innovative Therapies: Biological Response Modifiers". Journal of the Association of Pediatric Oncology Nurses 5, n.º 1-2 (janeiro de 1988): 26. http://dx.doi.org/10.1177/104345428800500109.
Texto completo da fonteMattison, Lars, e Paul Iaizzo. "PHRENIC NERVE RESPONSE TO CRYOABLATION THERAPIES". Journal of the American College of Cardiology 65, n.º 10 (março de 2015): A405. http://dx.doi.org/10.1016/s0735-1097(15)60405-3.
Texto completo da fonteCunningham, Jonathan W., e Peder L. Myhre. "NT-proBNP Response to Heart Failure Therapies". Journal of the American College of Cardiology 78, n.º 13 (setembro de 2021): 1333–36. http://dx.doi.org/10.1016/j.jacc.2021.07.045.
Texto completo da fonteGerger, Armin, Melissa LaBonte e Heinz-Josef Lenz. "Molecular Predictors of Response to Antiangiogenesis Therapies". Cancer Journal 17, n.º 2 (março de 2011): 134–41. http://dx.doi.org/10.1097/ppo.0b013e318212db3c.
Texto completo da fonteHeld, Barbara S. "Common dances, uncommon therapies: Response to Ryder." Journal of Family Psychology 1, n.º 4 (1988): 476–79. http://dx.doi.org/10.1037/h0084983.
Texto completo da fonteJohnston, Stephen R. D., Alexandra Leary, Lesley-Ann Martin, Ian E. Smith e Mitch Dowsett. "Enhancing endocrine response with novel targeted therapies". Cancer 112, S3 (2008): 710–17. http://dx.doi.org/10.1002/cncr.23190.
Texto completo da fonteTeses / dissertações sobre o assunto "Response to therapies"
Massó, Vallés Daniel. "Inhibiting Myc and the Myc dependent inflammatory response as cancer therapies". Doctoral thesis, Universitat Autònoma de Barcelona, 2017. http://hdl.handle.net/10803/458137.
Texto completo da fonteThe work of this thesis was carried out in the Mouse Models of Cancer Therapies Laboratory led by Dr. Laura Soucek in the Preclinical Research Program of the Vall d’Hebron Institute of Oncology (VHIO), and comprises two differentiated parts centered on two oncogenic functions of Myc. In the first project we validated the pharmacological inhibition of mast cells as a therapeutic strategy against pancreatic ductal adenocarcinoma (PDAC). To do so, we made use of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib in mouse models of PDAC, the most common and aggressive pancreatic tumor. Treatment with ibrutinib inhibited mast cell degranulation, reduced cell proliferation and leukocytic infiltration in the tumor stroma and dramatically reduced collagen deposition. In fibrotic mouse models of PDAC, both genetically-engineered and patient-derived, ibrutinib extended survival and synergized with chemotherapy, demonstrating the clinical applicability of this drug against pancreatic cancer. This project has led to the publication of a research paper and an editorial (Masso-Valles et al. 2015; Masso-Valles et al. 2016), as well as contributing to the initiation of clinical trials combining ibrutinib with chemotherapy in patients with metastatic PDAC (phase 1/2: NCT02562898 and phase 2/3: NCT02436668). The second project is focused on the relationship between Myc and metastasis. We studied de potential of Omomyc, a Myc dominant negative mutant that had shown extraordinary efficacy against primary tumors in multiple mouse models, against metastatic breast cancer. We demonstrated that Myc inhibition by Omomyc is a safe and effective therapy against breast cancer by impairing cell proliferation, angiogenesis, migration and invasion in vitro, dramatically reducing primary tumor and metastatic growth in immunocompromised mice, even eradicating established metastases, and preventing primary tumor and metastatic formation almost completely in immunocompetent mice. Thus, we have demonstrated for the first time the applicability of Omomyc against metastasis, challenging the pre-established notion that Myc inhibition could potentiate, rather than inhibit, invasion. Finally, we have validated TMTP1-Omomyc as the first direct-deliverable Omomyc-based drug for the treatment of metastatic triple negative breast cancer, providing a new therapeutic opportunity for patients suffering from this dreadful and incurable disease.
FATIMA, RIZWAN NARJIS. "Targeting the integrated stress response (ISR) as a therapeutic option for chronic lymphocytic leukemia". Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/25009.
Texto completo da fonteNji, Akindeh Mbuh. "Modeling response and delayance to parasite clearance time to artemisinin combination therapies(ACT)". Diss., Ludwig-Maximilians-Universität München, 2013. http://nbn-resolving.de/urn:nbn:de:bvb:19-168213.
Texto completo da fonteRandall, Adrian Joseph. "A systems approach to uncovering the adaptive response of cancer to targeted therapies". Thesis, Massachusetts Institute of Technology, 2012. http://hdl.handle.net/1721.1/72967.
Texto completo da fonteCataloged from PDF version of thesis.
Includes bibliographical references (p. 47-53).
Tyrosine kinase inhibitors have significant promise in the fight to develop agents that can target cancer in a tumor-specific manner. A number of drugs have been and are currently in development to inhibit specific kinases that can mediate uncontrolled proliferation; however, an unfortunate eventuality for most patients receiving these treatments is the development of resistance that renders these drugs almost completely ineffective. While a number of mechanisms can evolve within a tumor to mitigate effects of kinase inhibitors, we sought to uncover what changes are occurring in the tyrosine phosphorylation network at both short timescales (minutes to 72 hours) and long timescales (120 hours+) that can be playing a role in helping a tumor become resistant to driver-kinase inhibition. It is our hypothesis that specific feedback networks are able to detect and overcome driver kinase inhibition through activation of potential other pathways, which can go on to mediate a longer term resistance phenotype. In order to probe dynamics in the tyrosine phosphorylation network, we employed mass spectrometry to analyze peptides derived from six non-small cell lung cancer cell lines that we classify as either EGFR+ or EML4-ALK+. From both mass spectrometry data and growth assays, we identified an unintuitive boost in signaling and growth in response to low inhibitor concentrations, suggestive of a cellular mechanism that is adaptive to driver kinase inhibition. Studies of EML4-ALK driven H3122 cells showed that this short-term response is not the same as the known long-term resistance mechanism to ALK inhibition, leading support to the notion that the short-term "adaptive response" may be a novel type of mechanism to aid tumor adaptation to targeted therapies. In an effort to better probe signaling events occurring downstream of the phosphotyrosine network, a new pull down technique for mass spectrometry using 14-3-3 protein against phosphoserine and phosphothreonine peptides is described. The results of these studies open up many potential avenues for further exploration into the immediate and long-term signaling response of cancer to targeted therapies.
by Adrian Joseph Randall.
S.M.
Breen, Michael Scott. "TISSUE RESPONSE TO INTERVENTIONAL MRI-GUIDED THERMAL ABLATION THERAPY". Case Western Reserve University School of Graduate Studies / OhioLINK, 2004. http://rave.ohiolink.edu/etdc/view?acc_num=case1080938405.
Texto completo da fonteReddy, Papari Prashanth. "Non-motor symptoms in advanced Parkinson's : the natural history and response to advanced therapies". Thesis, King's College London (University of London), 2015. http://kclpure.kcl.ac.uk/portal/en/theses/nonmotor-symptoms-in-advanced-parkinsons(b82ce682-b4f0-424d-9c7e-9f293b11bc18).html.
Texto completo da fonteFenton, Audrey C. "The role of oncogenic kras as a determinant of response to EGER?HER2 targeted therapies". Thesis, Queen's University Belfast, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.534743.
Texto completo da fonteCramer, Megan L. "Novel signaling pathways in skeletal muscle: Modifiers of disease and the immune response to therapies". The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1531790292235549.
Texto completo da fonteMcNally, Jonathan P. "The rational targeting of the DNA damage response pathway for the selective elimination of encephalitogenic T cells". University of Cincinnati / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1428652709.
Texto completo da fonteBeshir, Kahlid Bushra. "Genetic polymorphisms in 'Plasmodium falciparum' associated with reduced response to artemisinin combination therapies in Western Kenya". Thesis, London School of Hygiene and Tropical Medicine (University of London), 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.558359.
Texto completo da fonteLivros sobre o assunto "Response to therapies"
Janusz, Rak, ed. Oncogene-directed therapies. Totowa, N.J: Humana Press, 2003.
Encontre o texto completo da fonteLoes, Michael, e Michael W. Loes. The healing response. Topanga, Calif: Freedom Press, 2002.
Encontre o texto completo da fonteCastro, Antonio de Miguel. Clopidogrel response in acute coronary syndrome: Clinical implications and emerging therapies. Hauppauge, N.Y: Nova Science Publishers, 2010.
Encontre o texto completo da fonteA, Foon Kenneth, e Muss Hyman B, eds. Biological and hormonal therapies of cancer. Boston: Kluwer Academic Publishers, 1998.
Encontre o texto completo da fonteL, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging. e International Symposium on Combination Therapies (1st : 1991 : Washington, D.C.), eds. Combination therapies: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1992.
Encontre o texto completo da fonteL, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging. e International Symposium on Combination Therapies (2nd : 1992 : Acireale, Italy), eds. Combination therapies 2: Biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1993.
Encontre o texto completo da fonteHoward, Brody. The placebo response: How you can release the body's inner pharmacy for better health. New York: Cliff Street Books, 2000.
Encontre o texto completo da fonteValentine, Tom. Applied kinesiology: Muscle response in diagnosis, therapy and preventive medicine. Rochester, Vt: Thorsons Publishers, 1987.
Encontre o texto completo da fonteValentine, Tom. Applied kinesiology: Muscle response in diagnosis, therapy, and preventive medicine. Rochester, Vt: Healing Arts Press, 1987.
Encontre o texto completo da fonteThe placebo response and the power of unconscious healing. New York: Routledge, 2008.
Encontre o texto completo da fonteCapítulos de livros sobre o assunto "Response to therapies"
Hsia, Judith, e Ting Tang. "Aspirin as a Biological Response Modifier". In Combination Therapies, 131–37. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_16.
Texto completo da fonteCassone, Antonio, Antonella Torosantucci, Carla Palma, Maria J. Gomez, Clara M. Ausiello e Julie Y. Djeu. "Cell Wall Constituents of Candida Albicans as Biological Response Modifiers". In Combination Therapies, 159–66. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_19.
Texto completo da fonteVenditti, Adriano, Maria Teresa Scimo, Giovanni Del Poeta, Roberto Stasi, Ugo Coppetelli, Mario Masi, Manrico Cecconi et al. "Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes". In Combination Therapies 2, 171–77. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2964-4_20.
Texto completo da fonteKirkley, J. E., Paul H. Naylor, Dante J. Marciani, Charlotte R. Kensil, Mark Newman e A. L. Goldstein. "QS-21 Augments the Antibody Response to a Synthetic Peptide Vaccine Compared to Alum". In Combination Therapies, 231–36. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_28.
Texto completo da fonteNakanishi, Toshio. "Thromboembolism in Cyanotic Heart Disease: Mechanisms and Therapies". In Inflammatory Response in Cardiovascular Surgery, 349–53. London: Springer London, 2013. http://dx.doi.org/10.1007/978-1-4471-4429-8_41.
Texto completo da fonteZhang-Hoover, Jie, e Joan Stein-Streilein. "Therapies Based on Principles of Ocular Immune Privilege". In Immune Response and the Eye, 317–27. Basel: KARGER, 2007. http://dx.doi.org/10.1159/000099281.
Texto completo da fonteMutchnick, Milton G., J. I. Jaurequi e David A. Shafritz. "Sustained Response to Thymosin Therapy in Patients with Chronic Active Hepatitis B". In Combination Therapies 2, 217–23. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2964-4_26.
Texto completo da fonteStolfi, Vito M., Jeffrey W. Milsom, James H. Finke, Victor W. Fazio, Luca Ferraris e Claudio Fiocchi. "The Biological Response Modifiers Interleukin-2 and Tumor Necrosis Factor-α Modulate the Cytotoxic Activity of Tumor Infiltrating Lymphocytes Against Human Colon Cancer Cells". In Combination Therapies, 245–51. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_30.
Texto completo da fonteRavagnan, Giampietro, Roberto Falchetti, Paolo Di Francesco, Roberta Gaziano, Giulia Lanzilli, Cartesio Favalli e Enrico Garaci. "Effect of Thymosin α 1 on Cocaine-Induced Inhibition of T-Cell Dependent Murine Immune Response". In Combination Therapies 2, 61–66. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2964-4_7.
Texto completo da fonteWood, Laura L. "Empirical Research Considerations in Drama Therapy: A Response Essay". In Arts Therapies in Psychiatric Rehabilitation, 155–57. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-76208-7_21.
Texto completo da fonteTrabalhos de conferências sobre o assunto "Response to therapies"
Berceli, Scott A., e Alexander W. Clowes. "Intimal Hyperplasia — Development and Regression in Response to Fluid Shear". In ASME 1999 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1999. http://dx.doi.org/10.1115/imece1999-0381.
Texto completo da fonteRUSSO, MARIANGELA, Giovanni Crisafulli, Alberto Sogari, Nicole Megan Reilly, Sabrina Arena, Simona Lamba, Alice Bartolini et al. "Abstract A120: Adaptive mutability of colorectal cancers in response to targeted therapies". In Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-a120.
Texto completo da fonteJohnsen, Hannah, Aphrothiti Hanrahan, Alexis Jones e David Solit. "Abstract 36: Functional characterization of ERBB2 mutations and response to targeted therapies". In Abstracts: AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy; June 13-16, 2015; Salt Lake City, UT. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1557-3265.pmsclingen15-36.
Texto completo da fonteLAURET, Simon, Laurent Guilleminault, Elise Noel-Savina, Gregoire Prevot, Danielle Brouquieres e Alain Didier. "Are serum immunoglobulins a predictive biomarker of response for anti-IL5 therapies?" In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.2266.
Texto completo da fonteDunne, Victoria L., Niamh McGivern, Kienan I. Savage, Nuala McCabe e Richard Kennedy. "Abstract 3163: The role of early response genes (ERG’s) as a biomarker of response to Wee1 targeted therapies". In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3163.
Texto completo da fonteDunne, Victoria L., Niamh McGivern, Kienan I. Savage, Nuala McCabe e Richard Kennedy. "Abstract 3163: The role of early response genes (ERG’s) as a biomarker of response to Wee1 targeted therapies". In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3163.
Texto completo da fonteBardelli, Alberto. "Abstract PL06-01: Liquid biopsies to monitor response and resistance to targeted therapies." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-pl06-01.
Texto completo da fontePrice, D., E. Sims, L. Kemp, J. von Ziegenweidt, T. Fan e AJ Lee. "Impact of Smoking and Rhinitis on Response to Therapies in Patients with Asthma." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5695.
Texto completo da fonteIto, Shuku-ei A., Hidekazu Shirota e Chikashi Ishioka. "Abstract 1454: IL-4 modulate the tumor microenvironment and response to cancer therapies". In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1454.
Texto completo da fonteRosa, Rogerio S., Rafael H. S. Santos, Adamo Y. Brito e Katia S. Guimaraes. "Insights on prediction of patients' response to anti-HIV therapies through machine learning". In 2014 International Joint Conference on Neural Networks (IJCNN). IEEE, 2014. http://dx.doi.org/10.1109/ijcnn.2014.6889659.
Texto completo da fonteRelatórios de organizações sobre o assunto "Response to therapies"
McCawley, Lisa. Breast Cancer Tissue Bioreactor for Direct Interrogation and Observation of Response to Antitumor Therapies. Fort Belvoir, VA: Defense Technical Information Center, julho de 2011. http://dx.doi.org/10.21236/ada552540.
Texto completo da fonteZhu, Zhihong, Yue Zhuo, Haitao Jin, Boyu Wu e Zhijie Li. Chinese Medicine Therapies for Neurogenic Bladder after Spinal Cord Injury: A protocol for systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, agosto de 2021. http://dx.doi.org/10.37766/inplasy2021.8.0084.
Texto completo da fonteWANG, Xuesong, Xuliang SHI, Jing LV, Juncha ZHANG, Yongli HUO, Guang ZUO, Guangtong LU, Cunzhi LIU e Yanfen SHE. Acupuncture and Related Therapies for anxiety and depression in Diarrhoea-Predominant Irritable Bowel Syndrome(IBS-D): A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, março de 2022. http://dx.doi.org/10.37766/inplasy2022.3.0162.
Texto completo da fonteFDG-PET/CT SUV for Response to Cancer Therapy, Clinically Feasible Profile. Chair Nathan Hall e Jeffrey Yap. Radiological Society of North America (RSNA) / Quantitative Imaging Biomarkers Alliance (QIBA), junho de 2023. http://dx.doi.org/10.1148/qiba/20230615.
Texto completo da fonteShujaa, Asaad Suliman, e Qasem Almulihi. The efficacy and safety of ketamine in treating refractory and super-refractory status epilepticus in pediatric and adult populations, A systemic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, novembro de 2022. http://dx.doi.org/10.37766/inplasy2022.11.0011.
Texto completo da fonteChou, Roger, Rongwei Fu, Tracy Dana, Miranda Pappas, Erica Hart e Kimberly M. Mauer. Interventional Treatments for Acute and Chronic Pain: Systematic Review. Agency for Healthcare Research and Quality (AHRQ), setembro de 2021. http://dx.doi.org/10.23970/ahrqepccer247.
Texto completo da fonteSionov, Edward, Nancy Keller e Shiri Barad-Kotler. Mechanisms governing the global regulation of mycotoxin production and pathogenicity by Penicillium expansum in postharvest fruits. United States Department of Agriculture, janeiro de 2017. http://dx.doi.org/10.32747/2017.7604292.bard.
Texto completo da fonteFamily Therapists Supporting the Hosts of Ukrainian Family (recording). ACAMH, dezembro de 2022. http://dx.doi.org/10.13056/acamh.21757.
Texto completo da fonteInternet‐delivered cognitive behavior therapy with minimal therapist support for anxious children and adolescents: predictors of response. ACAMH, junho de 2020. http://dx.doi.org/10.13056/acamh.12098.
Texto completo da fonte